Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic non-small cell lung cancer with an EGFR exon 20 insertion by an FDA-approved test, progressing during or after platinum chemotherapy. FDA withdrew this indication on July 15, 2024.
LAMPGEN ANALYSIS
Why it matters
The original accelerated approval was followed by withdrawal, which affects historical comparisons of post-platinum options.
What research teams should watch
Record exact EGFR genotype, platinum history and both FDA action dates.
PRIMARY RECORDS